About Marian Nakada
Form D filings for ONL Therapeutics in 2024 list Marian Nakada as director.
Marian Nakada first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Marian Nakada in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Marian Nakada works with at each company, as listed on that company's latest Form D.
ONL Therapeutics, Inc. · Form D, Sep 16, 2024
DE
David Esposito
CEO & President, director
CC
Constance Chang
Executive officer
AF
Aaron Fletcher
Director
MS
Michal Silverberg
Director
BB
Bill Burns
Director
DZ
David Zacks
Executive officer